Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has filed a shelf prospectus supplement. The filing is a supplement to MYCOF’s Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, which were dated earlier this year, in January 2022. According to the announcement, the prospectus supplement is the second supplement filed in connection to the subscription agreement. This supplement notes that Mydecine Innovations is qualifying the distribution of up to 943,396 common shares in the capital of the company to the investor for $0.53 per share, resulting in gross proceeds of almost $5 million. In addition, Mydecine Innovations closed the second issuance under the subscription agreement; that offering was comprised of 943,396 issued shares at $0.53 per share, resulting in gross proceeds of $499,999.88.
To view the full press release, visit https://ibn.fm/ibP8A
About Mydecine Innovations Group Inc.
Mydecine Innovations is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (“PTSD”). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine’s dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world’s leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more-effective treatment solutions. At the same time, Mydecine’s approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise. Based out of Colorado, Mydecine was founded in 2020, and has offices in Canada and the Netherlands.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.